Context Therapeutics reports positive interim Phase 1a data for ovarian cancer therapy
- Context Therapeutics (NASDAQ:CNTX) announced positive interim Phase 1a clinical trial data for CTIM-76, its CLDN6 x CD3 T cell engager targeting advanced platinum-resistant ovarian cancer (PROC).
- Efficacy-evaluable patients treated at active dose levels achieved an overall response rate (ORR) of 29% and a disease control rate (DCR) of 57%, with mostly low-grade, reversible adverse events.
- Backed by FDA Fast Track designation, the candidate's pharmacokinetic (PK) profile supports moving forward with a convenient every-three-weeks (Q3W) dosing schedule beginning in the second half of 2026.
Context Therapeutics (NASDAQ:CNTX) revealed encouraging preliminary clinical data from its Phase 1a trial evaluating CTIM-76, an investigational bispecific T cell engager designed to target claudin 6 (CLDN6) and engage CD3 T cells.
The trial focuses on patients with advanced platinum-resistant ovarian cancer (PROC), a historically hard-to-treat malignancy with limited therapeutic alternatives.
Among the patients who were evaluable for efficacy at active dose cohorts, CTIM-76 demonstrated a 29% overall response rate (ORR) and a 57% disease control rate (DCR).
Notably, three patients maintained disease control for six months or longer.
From a safety perspective, the treatment was generally well-tolerated, with adverse events characterized as predominantly low-grade and fully reversible.
Pharmacokinetic (PK) data compiled during the trial supports a transition to an every-three-weeks (Q3W) dosing regimen.
Context plans to initiate this updated schedule during the second half of 2026.
The development program is currently supported by an active FDA Fast Track designation for PROC.
Following the announcement, Context Therapeutics shares traded at $2.45.
